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Abstract: We describe the synthesis, characterization and application as contrast agents in magnetic
resonance imaging of a novel type of magnetic nanoparticle based on Gd-Si oxide, which presents
high Gd3+ atom density. For this purpose, we have used a Prussian Blue analogue as the sacrificial
template by reacting with soluble silicate, obtaining particles with nanorod morphology and of
small size (75 nm). These nanoparticles present good biocompatibility and higher longitudinal
and transversal relaxivity values than commercial Gd3+ solutions, which significantly improves the
sensitivity of in vivo magnetic resonance images.
Keywords: Prussian Blue analogues; Gd-Si nanoparticles; magnetic resonance imaging;
contrast agent
1. Introduction
One of the main reasons why cancer is a major medical challenge of the 21st century is that, in
many cases, therapy success is mostly affected by timely diagnosis and prognosis. In this sense, it is
crucial to find novel approaches of diagnostic techniques capable of detecting the malignancy at early
stages. Here, magnetic resonance imaging (MRI) is a non-invasive technique in medical research
that presents several advantages (use of non-ionizing radiation, widespread clinical implementation,
and good anatomical resolution) that make it one of the most powerful imaging techniques [1–3].
Contrast agents (CA) are used for multiple purposes in MRI, one of them being the clinical detection of
tumors [4]. Based on their relaxation processes, CAs are classified as T1-positive agents of paramagnetic
species and T2-negative agents of super-paramagnetic materials. Due to their high sensitivity and
detectability, Gd3+-based soluble chelates are the most representative and preferential T1 CAs in
current MRI clinical applications [5]. However, their poor pharmacokinetics profile, due to quick
renal filtration, limits the sensitivity [6]. This, consequently, requires the administration of generous
CA doses, e.g., perfusion studies for tumor detection, which may lead to some side effects such as
headache, nausea, and dizziness [7]. Among the most significant side effects reported regarding the
administration of Gd3+ compounds, we find nephrogenic systemic fibrosis in patients with impaired
kidney function, hypersensitivity reactions, and nephrogenic fibrosing dermopathy, which makes it
expedient to develop alternatives to these small, soluble molecules [8].
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At this point, magnetic nanoparticles (MNP) present several advantages over conventional Gd3+
CAs, such as large payloads of paramagnetic metal ions, extended plasma circulating half-lives, passive
accumulation at tumor sites, and improved safety profiles [9,10]. Therefore, the incorporation of Gd3+
in a stable nanocarrier points to the development of safe and efficient CAs for MRI. In this context, silica
nanomaterials have been recently considered to be excellent candidates for the preparation of drug
delivery systems and CAs. Firstly, their textural properties favor the loading of significant quantities
of therapeutic molecules within pore channels. Secondly, it is possible to obtain nanoparticles of these
materials, which results in an accurate control over pore structure, particle shape and size [11,12] and,
finally, the silanol-containing surface can be easily functionalized, introducing additional features that
allow imposing targeting delivery [13]. Furthermore, biocompatibility test results have shown the
potential of these materials in the preparation of pharmaceutical forms that might find application in
diagnostics and customized medicine [14].
The first attempt to create a silica-based Gd3+ CA was by incorporation, by covalent bonding
or by confinement, of a Gd3+ chelate [15–23]. This way, highly paramagnetic conjugates may be
obtained, in some cases with very impressive longitudinal (r1) and transversal (r2) relaxivity values.
However, Gd3+ concentration in these conjugates is usually low, which reduces the sensitivity for
in vivo applications. Moreover, metal leaching in biological fluids is not always negligible, which may
hinder administration of recurrent doses. More stable CAs can be prepared by doping the silica matrix
with Gd3+ cations [24–29], but the paramagnetic center density in the silicate network remains limited.
A possibility to increase the number of metal centers per particle and to avoid toxicity issues is to
protect small gadolinium nanoparticles with a silica shell [30–37]. These systems are very stable in
physiological medium and their main drawback is the low accessibility of the Gd3+ sites to water
molecules, due to the confining effects developed over the silica coating. It must be considered that the
r1 relaxivity is highly dependent on the number of water molecules coordinating to each metal ion
in the first hydration sphere (q), which plays a detrimental role in MRI properties of these materials,
especially when the present trend in clinical MRI is moving towards the use of higher magnetic field
strength to obtain a better signal to noise ratio (SNR).
In order to increase the number of metal centers per particle, without reducing the water
accessibility, an alternative is to develop Gd silicate-based MNP, where the high ion density and
a disordered structure allow for efficient interaction of most Gd3+ sites with the surrounding water [35].
On this basis, we introduce here a novel approach for the synthesis of Gd-Si oxide nanoparticles
with high Gd3+ atom density and excellent stability in physiological conditions. For this purpose,
we used an optimized method developed by our group [38], wherein Prussian Blue analogue (PBA)
Gd(H2O)4[Fe(CN)6] is used as a sacrificial template by reacting with soluble silicate. By overlapping
kinetics of silica condensation with [Fe(CN)6]3´ removal, we are able to synthesize particles of an oxide
nanocomposite with equal shape and size than former PBA crystallites. The resulting material presents
nanorod morphology, small particle size (75 nm average length), and shows good r1 and r2 relaxivity
values in a 3 tesla (T) magnetic field, improving positive contrast of in vitro and in vivo MRI images.
2. Results and Discussion
2.1. Materials Preparation and Characterization
Scheme 1 depicts the strategy to synthesize pre-formed Gd-Si oxide nanoparticles.
Firstly, an improved method for the preparation of GdFe PBA with small particle size was developed.
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Scheme 1. Synthesis layout of Gd-Si oxide nanorods using Gd(H2O)4[Fe(CN)6] as a sacrificial template. 
Rod-shaped, monodispersed, high-purity particles of 94 nm average diameter were obtained 
(see Table 1). The crystal structure of the tridimensional coordination network Gd(H2O)4[Fe(CN)6] 
has been recently solved [39]. The solid crystallizes in the orthorhombic system with Cmcm space group 
and cell parameter of a = 7.4016(3) Å , b = 12.78813 (16) Å , and c = 13.5980(12) Å . This nanosized MOF 
presents a fully comparable powder X-ray diffraction (XRD) pattern to that obtained for the bulk 
compound (Figure 1). Moreover, crystal composition, as determined by energy-dispersive X-ray 
spectroscopy analysis (EDS) analysis, is very homogeneous, with uniform Fe and Gd distribution 
within the particles, as revealed by elemental mapping results (Figure 2), which is strongly consistent 
with the stoichiometry of the metal-organic framework (MOF). 
Table 1. Compositional and textural characteristics of as-synthesized materials. 
Sample Molecular Formula 
Atomic composition (%) a 
Size 
(nm) Area BET (m2·g−1) b 
Gd Fe Si TEM c DLS d 
GdFe Gd(H2O)4[Fe(CN)6] 52.8 47.2 -- 94.2 ± 35.5 nd e nd e 
GdSi Gd(OH)3·3SiO2·xH2O 18.6 1.3 80.1 75.2 ± 24.0 84 ± 44 19.0 
a As determined from the energy-dispersive X-ray spectroscopy analysis (EDS) study. b Brunauer-
Emmett-Teller (BET) surface area analysis. c Avg ± SD, as determined by transmission electron 
microscopy (TEM) measurement of at least 200 particles. d Diffuse light scattering (DLS). e nd = not 
determined. 
 
Figure 1. Powder X-ray diffraction (XRD) pattern of as-made GdFe nanorods 
Gd(H2O)4[Fe(CN)6] Gd(OH)3·SiO2·xH2O
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(1) Gd(NO3)3·6H2O in EtOH:H2O (2.5:1 v/v)
(2) Na2SiO3 in EtOH:H2O (2.5:1 v/v)
(3) APTES in anhydrous toluene
(4) PEG4 in anhydrous CH2Cl2
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Scheme 1. Synthesis layout of Gd-Si oxi e nanoro s using ( 2 )4[Fe( )6] as a sacrificial te plate.
Rod-shaped, monodispersed, high-purity particles of 94 nm average diameter were obtained
(see Table 1). The crystal structure of the tridimensional coordination network Gd(H2O)4[Fe(CN)6]
has been recently solved [39]. The solid crystallizes in the orthorhombic system with Cmcm space
group and cell parameter of a = 7.4016(3) Å, b = 12.78813(16) Å, and c = 13.5980(12) Å. This nanosized
MOF presents a fully comparable powder X-ray diffraction (XRD) pattern to that obtained for the
bulk compound (Figure 1). Moreover, crystal composition, as determined by energy-dispersive X-ray
spectroscopy analysis (EDS) analysis, is very homogeneous, with uniform Fe and Gd distribution
within the particles, as revealed by elemental mapping results (Figure 2), which is strongly consistent
with the stoichiometry of the metal-organic framework (MOF).
Table 1. Compositional and textural characteristics of as-synthesized materials.
Sample Molecular Formula
Atomic Composition (%) a Size (nm) Area BET
(m2¨g´1) bGd Fe Si TEM c DLS d
GdFe Gd(H2O)4[Fe(CN)6] 52.8 47.2 – 94.2 ˘ 35.5 nd e nd e
GdSi Gd(OH)3¨ 3SiO2¨ xH2O 18.6 1.3 80.1 75.2 ˘ 24.0 84 ˘ 44 19.0
a As determined from the energy-dispersive X-ray spectroscopy analysis (EDS) study; b Brunauer-Emmett-Teller
(BET) surface area analysis; c Avg˘ SD, as determined by transmission electron microscopy (TEM) measurement
of at least 200 particles; d Diffuse light scattering (DLS); e nd = not determined.
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Figure 1. Po der X-ray dif raction (XRD) pat ern of as-made GdFe nanorods.
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Figure 2. Electron microscopy study of as synthesized GdFe nanorods. (a–b): Transmission electron 
microscopy (TEM) (a) and field-emission scanning electronic microscopy (FESEM) (b) images. (c) 
Scanning transmission electron microscopy (STEM) image with energy-dispersive X-ray spectroscopy 
analysis (EDS) line scans. Legend: blue line = Gd; red line = Fe. (d–f): STEM image (d) and EDS 
mapping pictures of one GdFe nanorod (e–f). 
Such GdFe small crystallites are partially soluble in neutral water, and an ion exchange reaction 
takes place in alkaline solution resulting in complete MOF dissolution, as follows Equation (1): 
Gd(H2O)4[Fe(CN)6](s) + 3OH−(aq) ↔ Gd(OH)3(s) + [Fe(CN)6]3−(aq) + 4H2O (1)  
This reaction can be carried out in the presence of silicate ions, the hydrolysis of which provides 
enough OH− concentration for the transformation. Therefore, under optimized conditions, it is 
possible to overlap ion exchange of the PBA with the hydrolysis of the conjugate base, and, as a 
consequence, a simultaneous and stoichiometric condensation of gadolinium hydroxide and silica 
takes place. This process is defined by Equation (2): 
2Gd(H2O)4[Fe(CN)6](s) + 3SiO32−(aq) + 3(1+x)H2O  
↔ 2Gd(OH)3·3SiO2·xH2O(s) + 2[Fe(CN)6]3−(aq) + 4H2O 
(2) 
Dense, monodispersed Gd-Si oxide nanoparticles (GdSi) are obtained mostly preserving the 
original rod shape and size of the sacrificial GdFe crystals. The reaction proceeds slowly at room 
temperature in a silicate solution (EtOH:H2O, 2.5:1 v/v). This way, MOF particles are gradually 
consumed, releasing Fe(CN)63− as hydroxide ions diffuse inward, and a composite of Gd(OH)3 and 
SiO2 is formed. The powder XRD pattern shows an amorphous material (figure not shown), with BET 
surface area of about 19.0 m2·g−1 and low porosity (Table 1). This nanohybrid low crystallinity is due 
to mutual inhibition of crystal growth between the highly-dispersed Gd(OH)3 and SiO2 [40]. 
Electron microscopy study by TEM and FESEM (Figure 3) confirms that morphology does not 
experience significant changes, although nanosized rods present a slightly smaller average diameter 
(75 nm). As already detected with other morphologies at the nanoscale [38], our transformed particles 
are fully dense, what contrasts with observations by Lou and co-workers over Prusian Blue microbox 
derivatives [40,41]. We attribute such different material features to the nanoscale, as the inward OH− 
ion diffusion is faster in smaller particles and 2Gd(OH)3·3SiO2·xH2O moiety precipitates quickly to 
refill the empty space left by released [Fe(CN)6]3− species. EDS analysis is consistent with the expected 
stoichiometry (Gd:Si atomic ratio of about 2:3), and demonstrates almost complete iron removal 
(Table 1). Moreover, the spatial distribution of Gd(OH)3 and SiO2 in isolated particles can be clearly 
seen by elemental mapping (Figure 3c–h), which illustrates both the homogeneous distribution of Gd 
and Si, and iron extraction. 
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Figure 2. El ctron micros opy study of as synt ed GdFe anorods. (a,b): Transmission electron
microscopy (TEM) (a) and field-emission scanning electronic microscopy (FESEM) (b) images;
(c) Scanning transmission electron microscopy (STEM) image with energy-dispersive X-ray
spectroscopy analysis (EDS) line scans. Legend: blue line = Gd; red line = Fe; (d,f): STEM image (d) and
EDS mapping pictures of one GdFe nanorod (e,f).
Such GdFe small crystallites are partially soluble in neutral water, and an ion exchange reaction
takes place in alkaline solution re ulting in complete MOF dissolution, as follows Equation (1):
GdpH2Oq4rFepCNq6spsq ` 3OH´paqqØGdpOHq3psq ` rFepCNq6s3´paqq ` 4H2O (1)
This reaction can be carried out in the presence of silicate ions, the hydrolysis of which provides
enough OH´ oncent ation for the transformation. Therefore, under optimized conditions, it is
possible to overlap ion exchange of the PBA with the hydrolysis of the conjugate base, and, as
a consequence, a simultaneous and stoichiometric condensation of gadolinium hydroxide and silica
takes place. This process is defined by Equation (2):
2GdpH2Oq4rFepCNq6spsq ` 3SiO32´paqq ` 3p1 ` xqH2O
Ø 2GdpOHq3¨ 3SiO2¨ xH2Opsq ` 2rFepCNq6s3´paqq ` 4H2O (2)
Dense, monodispersed Gd-Si oxide nanoparticles (GdSi) re o tained mostly preserving the
original rod shape and size of the sacrificial GdFe crystal . The reaction proceeds slowly at room
temperature in a silicate solution (EtOH:H2O, 2.5:1 v/v). This way, MOF particles are gradually
consumed, releasing Fe(CN)63´ as hydroxide ions diffuse inward, and a composite of Gd(OH)3 and
SiO2 is formed. The powder XRD pattern shows an amorphous material (figure not shown), with BET
surface area of about 19.0 m2¨ g´1 and low porosity (Table 1). This nanohybrid low crystallinity is due
to mutual inhibition of crystal growth between the highly-dispersed Gd(OH)3 and SiO2 [40].
Electron microscopy study by TEM and FESEM (Figure 3) confirm tha morphology does not
experience significant changes, although nanosized ro s present a slightly smaller average diameter
(75 nm). As already detected with other morphologies at the nanoscale [38], our transformed particles
are fully dense, what contrasts with observations by Lou and co-workers over Prusian Blue microbox
derivatives [40,41]. We attribute such different material features to the nanoscale, as the inward OH´
ion diffusion is faster in smaller particles and 2Gd(OH)3¨ 3SiO2¨ xH2O moiety precipitates quickly
to refill the empty space left by released [Fe(CN)6]3´ species. EDS analysis is consistent with the
expected stoichiometry (Gd:Si atomic ratio of about 2:3), and demonstrates almost complete iron
removal (Table 1). Moreover, the spatial distribution of Gd(OH)3 and SiO2 in isolated particles can be
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clearly seen by elemental mapping (Figure 3c–h), which illustrates both the homogeneous distribution
of Gd and Si, and iron extraction.
The GdSi sample presents a good stability pattern for use in biological medium. In this context, the
hydrodynamic diameter, as determined by diffuse light scattering (DLS) (Figure 4), is 83.9˘ 44.1 nm, is
very close to that determined by TEM, and with a narrow size distribution, which indicates that most
of the particles are monodispersed. Furthermore, dissolution tests carried out for 24 h in phosphate
buffer saline (PBS) and in an isotonic glucose aqueous solution revealed no detectable leaching of Gd3+
and/or Si4+ cations in the incubation medium.
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Figure 3. Electron microscopy study of GdSi nanorods obtained by alkaline transformation of GdFe
precursor. (a,b): TEM (a) and FESEM (b) images of GdSi nanoparticles; (c) EDS elemental analysis;
(d) STEM image with EDS line scans. Legend: blue line = Gd; red line = Fe; green line = Si; (e–h) STEM
image (e) and EDS mapping pictures of two GdSi nanorods (f–h).
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2.2. Relaxivity Measurements and In Vitro MRI
The efficacy of GdSi s T1- or T2-w ighted CA for MRI was evaluated by meas ring the
longitudinal (r1) and transversal (r2) nuclear magnetic relaxation r tes of water protons in aqueous
suspensions at 3 T and room temperature. Stable colloids were prepared in aqueous xanthan gum
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(0.1%) solution with Gd3+ concentration in the range 0–1.00 mM. Relaxivity values were determined
by using the following expression [42]:
1
Ti pwq
“ 1
Tip0q
` ri (3)
where i = 1 or 2 values, respectively, for longitudinal or transversal-weighted effect of CA. 1/Ti(w) is
the global relaxation rate constant of bulk water molecules, Ti(0) is the water relaxation time without
contrast agents (CA), and C is the paramagnetic ion concentration. Therefore, r1 and r2 values were
determined, respectively, from the plot slopes of 1/T1 (s´1) and 1/T2 (s´1) versus Gd3+ concentration
(mM, Table 2 and Figure 5). For the sake of comparison, same measurements were carried out with
commercial CA gadopentetate dihydrogen salt (Gd-DTPA, Aldrich). CAs can be classified according
to their T1 or T2 lowering activity. Moreover, when r2/r1 value is close to 1, application as a positive
(bright) CA is favored, whereas if this ratio increases far from 1 the CA works better for negative (dark)
contrast [43].
Table 2. Relaxivity properties for sample GdSi sample and commercial gadopentetate dihydrogen
salt (Gd-DTPA).
Sample r1/s´1¨mM´1 r2/s´1¨mM´1 r2/r1
GdSi 5.6 8.2 1.4
Gd-DTPA 4.1 3.3 0.8
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As it can be seen in Table 2, GdSi sa ple shows longitudinal and transversal relaxivity values,
respectively, 1.4 and 2.5 times higher than those corresponding to the soluble Gd3+ complex. This is in
agreement with other authors’ observations for different Gd silicate nanoparticles [37]. At this point,
the high Gd concentration (320 mg/g) present in this material should be considered. With regards
to the mononuclear Gd3+ complex, such a large density of paramagnetic centers in the nanoparticle
shortens T1 and T2 scores due to a cooperative effect and accessibility of all Gd3+ centers (surface
and core) [39]. Therefore, it is noticeable that no diffusion restrictions are present between ater
molecules and Gd3+ sites located in the silicate matrix. Additionally, it must be taken into account that
the presence of a small Fe3+ quantity in the as-synthesized GdSi sample (Table 1) might contribute to
a reduced T2 value. In this sense, with a r2/r1 ratio of about 1.5, this material is expected to improve
MRI images mostly in positive contrast. To further check the capability of the GdSi nanomaterial, we
collected phantom MRI images (Figure 6). The phantom was scanned with a single slice in coronal
orientation with variable CA or gadopentetate concentration. Results show that T1 images become
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progressively brighter as nanoparticle content increases (Figure 6a,b). Furthermore, T2-weighted
images become darker with Gd3+ concentration, but with lower significance than the positive contrast
(Figure 6c). In all cases, the sensitivity of this system is higher than that of the commercial Gd3+ chelate.
This encouraged us to test these MNPs in biological conditions, as described in the next two sections.
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Figure 6. T1-weighted (left) and T2-weighted (right) magnetic resonance imaging (MRI) slices of GdSi
aqueous solutions (0.1% xanthan gum), with varying Gd3+ concentration, at magnetic field of 3 T and
echo time of 2 ms (T1) and 203 ms (T2).
2.3. Cytotoxicity Test
I order to valid te the potential performance of the Gd-Si nanoparticles in a biological
environment, cell viability was assessed 24 h after incubation with the GdSi sample by measuring the
conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its formazan
form following standard procedures. For these experiments we used healthy fibroblasts (3T3 cell
line) and several cancer cell lines (HeLa cells, 42-MG-BA glioblastoma multiforme cells and SH-SY5Y
neuroblastoma cells) at a range of concentrations (0.25–100 µg¨mL´1). Results (Figure 7) indicate that
cell survival was always of about 70% or higher, even at maximum particle concentration. Despite MTT
assay limitations for accurate cell viability determination, these results correspond to an acceptable
biocompatibility profile.
Nanomaterials 2016, 6, 109 7 of 14 
 
commercial Gd3+ chelate. This encouraged us to test these MNPs in biological conditions, as described 
in the next two sections. 
 
 
Figure 6. T1-weighted (left) and T2-weighted (right) magnetic resonance imaging (MRI) slices of GdSi 
aqueous solutions (0.1% xanthan gum), with varying Gd3+ concentration, at magnetic field of 3 T and 
echo time of 2 ms (T1) and 203 ms (T2). 
2.3. Cytotoxicity Test 
In order to validate the potential performance of the Gd-Si nanoparticles in a biological 
environment, cell viability was assessed 24 h after incubation with the GdSi sample by measuring the 
conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its formazan 
form following standard procedures. For these experiments we used healthy fibroblasts (3T3 cell line) 
d several cancer cell ines (HeLa cells, 42-MG-BA glioblastoma ultiforme cells and SH-SY5Y 
neuroblastoma cells) at  range of concentrations (0.2  ·mL−1). Results (Figure 7) indicate that 
cell survival was always of about 70% or higher, even at maximum particle concentration. espite 
MTT assay limitations for accurate cell viability determination, these results correspond to an 
acceptable biocompatibility profile. 
  
Figure 7. In vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assays in different cell lines incubated with variable concentrations of GdSi magnetic nanorods (mean 
± SEM, n = 4). Top X-axis indicates the concentration of equivalent Gd3+. 
2.4. In Vivo MRI Studies Imaging 
It is well known that when introducing non-protected nanoparticles in blood, these suffer from 
strong protein adsorption, resulting in protein corona formation, which promotes further interaction 
with cell elements of the reticuloendothelial system (RES) [44]. As a consequence, particles are rapidly 
cleared from blood and accumulated in RES tissues, mainly the liver, spleen, and lungs. Consequently, 
GdSi
Gd-DTPA
0 mM 0.05 mM 0.10 mM 0.20 mM 1.00 mMT1
GdSi
Gd-DTPA
0 mM 0.05 mM 0.10 mM 0.20 mM 1.00 mMT2
110
50
0 100
60
70
80
90
100
0.25 0.50 1 10 20 40 60 80
HeLa
Fibroblast 3T3
Glioblastoma 42MGBA
Neuroblastoma SH-SY5Y
C
e
ll
V
ia
b
il
it
y
/%
GdSi/mg mL-1
0 2000.50 1 2 20 40 80 120 160
Gd3+/nM
Figure 7. In vitro 3-(4,5-dimethylthiazol-2-yl)- , - i henyltetrazolium bromide (MTT) cell viability
assay in different cell li incubated with variable concentrations of GdSi magnetic nanorods
(mean ˘ SE , n = 4). Top X-ax s indicates the concentration of equivalent Gd3+.
2.4. In Vivo MRI Studies Imaging
It is well known that when introducing non-protected nanoparticles in blood, these suffer from
strong protein adsorption, resulting in protein corona formation, which promotes further interaction
with cell elements of the reticuloendothelial system (RES) [44]. As a consequence, particles are
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rapidly cleared from blood and accumulated in RES tissues, mainly the liver, spleen, and lungs.
Consequently, for the in vivo study of GdSi contrast material, we firstly modified nanorod surfaces
with a short polyethyleneglycol (PEG) chain, according to a recipe developed by our group [45].
This way, nanoparticles are expected to prolong circulation in the blood stream, finally being removed
from the body mostly by renal (urine) and hepatic (biliary) routes [46,47]. Then, 1.0 mL of a 5 mg¨mL´1
GdSiPEG stable colloid in glucose 5.5% was perfused into the catheterized tail vein of healthy male
Sprague-Dawley rats as a bolus (0.04 mmol Gd kg´1). Subsequently, T1- and T2-weighted images were
acquired before (baseline) and after the administration of the CA by using a 7 T horizontal scanner.
Figure 8 shows coronal T1-weighted images depicting kidneys (Figure 8a,b, red arrows) and liver
(Figure 8c,d, red arrows), respectively, before (Figure 8a,c) and after (Figure 8b,d) CA administration.
These organs receive most of the blood stream showing highly significant particle accumulation, which
promotes a noticeable MRI T1 contrast enhancement. Kidneys showed a 7% increase in the MRI signal
intensity (SI) after the CA administration. Liver presented non-homogenous changes, probably due to
restricted nanoparticle biodistribution and pharmacokinetics, with some areas depicting large changes
up to 21% (Figure 8c,d, arrowhead), whereas other areas showed no changes or even a decrease in SI.
The contrast enhancement in the liver stands for at least one hour, the time we followed the contrast
agent by MRI. We can hypothesize that contrast will be enhanced for longer because when we stopped
the acquisition we were still able to detect a signal intensity enhancement with respect to baseline.
We are aware that similar MRI T1 contrast increase has also been recently reported with other
paramagnetic nanoparticles [48,49]. However, the GdSi system shows improved stability and a superior
safety profile in biological fluids, as no cation leaching was observed in dissolution tests carried
out for 24 h. Moreover, although this is not the aim of this work, in the case of application to
tumor development study, GdSi nanoparticle delivery to cancer cells may be promoted by surface
incorporation of specific moieties that target upregulated peptides in rapidly-dividing cells [50].
Conversely, despite the good MRI in vitro results formerly presented for T1, we must say that no
significant change was observed in T2 weighted images following CA administration.
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Figure 8. In vivo coronal T1-weighted images acquired from a male Sprague-Dawley rat at 7 T magnetic
field. (a,c) Control (baseline) with no MNP administration; (b,d) Acquisition 30 min after GdSi
nanoparticles injection (0.04 mmol Gd3+ kg´1); Red lines show up kidneys (a,b) and liver (c,d).
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3. Experimental Section
3.1. Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), except Gd(NO3)3¨ 6H2O
(ABCR, Karlsruhe, Germany) and HPLC grade solvents (Scharlab, Barcelona, Spain). Gd-Si oxide
nanoparticles protected with a PEG external coating were synthesized in a three-step process (Figure 1).
HeLa cell line, D6-3T3 (fibroblasts cells), 42-MG-BA (glioblastoma multiforme cells), and
SH-SY5Y (neuroblastoma cells), were purchased from the German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany. Reagents used for cells growth were MEM Eagle,
RPMI Medium 1640, DMEM, and Ham (F12) Nut MIX (Gibco BRL-Life Technologies, CA, USA)
fetalbovine serum (FBS), and penicillin/streptomycin solution (Pen-Strep). Dimethyl sulfoxide
(DMSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
Male Sprague-Dawley rats (250–300 g) (three specimens) were acquired from Janvier Labs (France)
and maintained under a 12/12-h light/dark cycle (lights on 07:00–19:00 h) at room temperature
(22 ˘ 2 ˝C), with free access to food and water. Rats were housed in group and adapted to these
conditions for at least one week before experimental manipulation. All experiments were approved by
the local authorities (CSIC-UMH) and were performed in accordance with Spanish (law 32/2007) and
European regulations (EU directive 86/609, EU decree 2001-486).
3.2. Synthesis of Gd(H2O)4[Fe(CN)6]
Firstly, we prepared the (Et4N)3[Fe(CN)6] precursor following a known recipe [51]. Briefly, 3.3 g
(10 mmol) of K3[Fe(CN)6] and 6.3 g (30 mmol) of Et4NBr were dissolved with 200 mL of methanol in
a 500 mL flask connected to a nitrogen line, and stirred at 30 ˝C for three days under N2 atmosphere.
The mixture was filtered off and the filtrate was concentrated to approximately 10 mL by rotary
evaporation. The resulting solution was stirred with 100 mL of ethyl ether and the yellow precipitate
was collected by filtration. The crude was dissolved in 150 mL of refluxing acetonitrile and the solution
was allowed to cool, obtaining (Et4N)3[Fe(CN)6]. For nanosized Prussian Blue analogue preparation,
Gd(NO3)3¨ 6H2O (0.86 g, 2.5 mmol) were dissolved in 50 mL of EtOH:H2O (2.5:1 v/v). Then, a solution
of the previously-synthesized (Et4N)3[Fe(CN)6] (1.5 g, 2.5 mmol, in 15 mL methanol) was added and
the mixture was left for a day at room temperature. The precipitate was filtered off, washed with
ethanol, and vacuum dried to yield 118 mg of an orange powder (GdFe).
3.3. Synthesis of GdSi Oxide/hydroxide Nanocomposite
Dense, Gd(OH)3¨ 3SiO2¨ xH2O nanoparticles (GdSi) were prepared by modification of a previously
reported method [40,41]. Gd(H2O)4[Fe(CN)6] (550 mg, 1.25 mmol), was suspended in 278 mL of
EtOH:H2O (2.5:1 v/v) with vigorous stirring. Then, 3-cyanopropiltrichlorosilane (697 µL, 4.50 mmol)
was added and, after 30 min, 3.5 mL ammonia solution and 11 mL of sodium silicate solution (0.54%
SiO2, 2.69 mmol) were introduced. The reaction was allowed to proceed for 48 h. Non-reacted silicate
ions were removed by subsequent centrifugation (484 g, 2 h), and the obtained white solid was washed
repeatedly with milliQ water, centrifuged again (1935 g, 30 min), and further freeze dried (´55 ˝C,
16 h).
In order to modify the GdSi surface, we used a method previously described by our group [45].
375 mg of Gd(OH)3¨ 3SiO2¨ xH2O was dried at 80 ˝C and vacuum (8 torr) for 24 h. Afterwards, 7.4 mL
of anhydrous toluene was added and the mixture was heated to reflux. Then, 728 µL (3.13mmol) of
3-aminopropyltriethoxysilane (APTES) was added and the mixture was stirred for 3 h. The obtained
product was filtered off, washed with toluene and methanol and freeze-dried (´55 ˝C, 16 h).
Next, 156 mg of the above material was suspended in 15.6 mL of anhydrous dichlorometane.
Then, 195 µL of diisopropyl amine were injected under nitrogen atmosphere. Afterwards, 234 mg
of 2,5,8,11-tetraoxatetradecan-14-oic acid succinimidyl ester (PEG4) was added. The reaction was
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stirred overnight at room temperature. Later, the solvent was removed under reduced pressure and
the nanoparticles were suspended in 100 mL of ethanol with stirring. Subsequently, the suspension
was filtered off and washed with ethanol (300 mL). Finally, the material (GdSiPEG) was freeze-dried
(´55 ˝C, 16 h).
3.4. Materials Characterization
Powder X-ray diffraction (XRD) patterns were collected in a Philips X’Pert diffractometer
equipped with a graphite monochromator, operating at 40 kV and 45 mA and using nickel-filtered
Cu Kα radiation (λ = 0.1542 nm). Liquid nitrogen adsorption isotherms of 200 mg of sample
were measured in a Micromeritics Flowsorb apparatus. Surface area calculations were done by
the BET method. Samples for transmission electron microscopy (TEM) were ultrasonically dispersed
in a mixture of EtOH:H2O (2.5:1 v/v) and transferred to carbon-coated copper grids. TEM and
scanning transmission electron microscopy (STEM) micrographs were collected in a JEOL JEM 2100F
microscope operating at 200 kV. The quantitative energy-dispersive X-ray spectroscopy analysis (EDS)
was performed in an INCA Energy TEM 250 system from Oxford Instruments, working with a SDD
X-MAX 80 detector. Field-emission scanning electron microscopy (FESEM) micrographs were collected
in a ZEISS Ultra 55 microscope operating at 2 kV, with a 2 ˆ 10´9 A beam current and 2.5 mm as the
working distance. Infrared spectra were recorded at room temperature in the 400´3900 cm´1 region
with a Nicolet 205xB spectrophotometer, equipped with a Data Station, at a spectral resolution of
1 cm´1 and accumulations of 128 scans. Samples were outgassed at 400 ˝C under vacuum during 1 h for
complete water removal before acquisition. Finally, water and organic (PEG3) content were calculated
from elemental analysis (FISONS, EA 1108 CHNS-O) and thermogravimetric (TGA) measurements
(Mettler-Toledo TGA/SDTA851e).
3.5. Stability Assays
GdSiPEG material stability in physiological medium was monitored by solution assay in
phosphate-buffered saline (PBS, 1ˆ) or glucose aqueous solution (5.5 wt. %). 5 mg of the corresponding
material were stirred in 1 mL at 1500 rpm and 37 ˝C in a Thermomixer® for 24 h. Then, samples were
centrifuged (16,100 g, 15 min) and supernatant metal cation concentration was analyzed by inducted
couple plasma (ICP).
3.6. Cell Biocompatibility
The different cell lines were cultured in 96-well cell culture plates with the seeding densities
shown below in a final medium volume of 200 µL/well: HeLa 10,000 cells/mL; fibroblast 3T3 and
glioblastoma 42-MGBA 50,000 cells/mL and neuroblastoma SH-SY5Y 100,000 cells/mL. HeLa cells
were grown in MEM (Earle’s), 3T3 cell line in DMEM, 42-MGBA cell line in MEM (Earle’s) and
RPMI 1640 (1:1), and SH-SY5Y cell line was cultured in a DMEM and Ham (F12) Nut MIX (1:1).
Cell media were supplemented with 10% FBS and Pen-Strep 1:100 (v/v). The plates were cultured 24 h
at 37 ˝C and 5% CO2 injection in air. After 24 h cells were treated with the CA at a concentration range
of about 0.25–100 µg/mL in RPMI medium. Cells with nanoparticles were incubated at 37 ˝C for 24 h
and 5% CO2. All concentrations were tested in triplicate and negative controls with no nanoparticles
were also carried out.
Cell viability was measured using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Briefly, 200 µL/well of MTT/PBS (1 mg/mL) were added and the plates
were incubated at 37 ˝C for 3 h. Formazan crystals were dissolved with 100 µL DMSO and then
absorbance at 595 nm was measured with a 1681130 iMarkTM Microplate Reader. Absorbance values
were normalized with respect to the control and expressed in percentage using the next Equation (4):
Relative cell viability “ OD595 TEST SAMPLE
OD595 CONTROL
ˆ 100 (4)
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Data statistical analysis was performed applying arithmetic’s means and error bars of statistical
error means (SEM) using MATLAB (MathWorks).
3.7. 1H NMR Relaxometry Study and In Vitro MRI.
Relaxivity determinations and MRI studies were carried out in a clinical 3 T MRI unit (Philips
Achieva 3 T X-Series; Philips Healthcare, The Netherlands) with an eight-channel phased array head
coil. The phantom was scanned with a single slice in the coronal orientation, obtaining a transversal
view of all tubes filled with variable CA concentration. Geometric parameters remain equivalent
between the T2 and T1 estimation sequences (field of view 220 ˆ 220 mm2, slice thickness 5 mm
and 1.0 ˆ 1.0 mm2 in plane resolution) sharing the same spatial localization. A multi-echo spin echo
sequence was used to estimate T2 values acquiring 32 echoes ranging from 14 to 231 ms (∆TE = 7 ms)
with a sequence TR of 2000 ms. T1 values of each tube were estimated using a look-locker inversion
recovery acquisition with 107 inversion times ranging from 6.51–5306.51 ms, with an inversion time
interval of 50 ms. A new inversion pulse was applied every 6 s to avoid signal saturation due to
extremely close inversion pulses. To reduce the influence of readout excitation pulse in the final
T1 values, an excitation flip angle of 5˝ was applied during the TFE shot [47]. With regards to
image analysis, T2 maps were generated by nonlinear fitting of the signal acquired at every TE to
a mono-exponential model. The same procedure was applied to every image pixel producing T2 maps.
Moreover, T1 maps were generated by nonlinear fitting of the signal acquired at every inversion time
to the signal model described at [52]. As in the case of T2 maps, the same procedure was applied to
every image pixel to generate the final T1 map. Quantitative values were obtained in aqueous xanthan
gum (0.1%) nanoparticle suspensions by manual region of interest (ROI) analysis over T2 and T1
maps. A circular ROI was placed for each tube, avoiding the border. In each ROI, means and standard
deviations were computed for further comparison. The resulting T1 and T2 values were averaged and
plotted as 1/Ti (s´1) where i = 1, 2 versus [Gd3+] (mM), the slopes of these graphs provided the specific
relaxivities r1 and r2.
3.8. In Vivo MRI Studies Imaging
Rats were anesthetized in an induction chamber with 3%–4% isofluorane in medical air
(0.8–1 L/min) and maintained with 1%–2% isofluorane (IsoFlo) during the MRI experiment.
Anesthetized animals were taped down in a custom-made animal holder to minimize breathing-related
movement artifacts. The body temperature was kept at 37 ˝C using a water blanket and animals
were monitored using a MRI-compatible temperature control unit (MultiSens Signal conditioner,
OpSens, Quebec, Canada). The breathing rate was also measured using a custom designed device.
Experiments were carried out in a horizontal 7 T scanner with a 30 cm diameter bore (Biospec
70/30v, Bruker Medical, Ettlingen, Germany). The system had a 675 mT/m actively-shielded gradient
coil (Bruker, BGA 12-S) of 11.4 cm inner diameter. A 1H rat body receive-transmitter resonator
(Bruker BioSpin MRI GmbH, Germany) was employed. Data were acquired with a Hewlett-Packard
console running Paravision software (Bruker Medical GmbH, Ettlingen, Germany) operating on
a Linux platform.
Studies were performed by injecting 1 mL of the CA suspension (5 mg¨mL´1) into the catheterized
tail vein as a single bolus (0.04 mmol Gd/kg body weight), and acquiring images 30 min afterwards.
Acquisition was held for 1 h. T2-weighted anatomical images to position the animal were collected
in the three orthogonal orientations using a rapid acquisition relaxation enhanced sequence (RARE),
applying the following parameters: field of view (FOV) 40 ˆ 40 mm, 15 slices, slice thickness 1 mm,
matrix 256 ˆ 256, effective echo time (TEeff) = 56 ms, repetition time (TR) = 2 s, 1 average and a total
acquisition time of 64 s [53,54]. Two types of images were used to assess the effect of CA in the signal
intensity in T1- and T2-weighted images. For the former, FLASH images were acquired with the
following parameters: 25 slices, 1.5 mm slice thickness, TR = 197 ms; TE = 2.7 ms; FOV = 6.0 ˆ 5.0 cm;
Mtx = 128 ˆ 108; averages = 4; total acquisition time = 90 s. Three images were acquired before the
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CA administration (baseline) and 20 after it. For the T2-weighted images, RARE was used with the
same geometry than the T1-weighted images and the following parameters: TR = 2800 ms; TE = 48 ms;
FOV = 6.0 ˆ 5.0 cm; Mtx = 256 ˆ 214; averages = 8; total acquisition time = 600 s. One of these images
was acquired at the beginning (baseline) and one at the end of the experiment. Data were analyzed
with Image J (W. S. Rasband, U.S. National Institutes of Health, Bethesda, MD, USA).
4. Conclusions
Gd-Si oxide nanoparticles obtained by alkaline transformation of a Prussian Blue analogue are
a novel MRI contrast agent with higher longitudinal and transversal in vitro relaxivity values than
commercial Gd3+ chelate solutions, excellent stability in physiological fluids, no significant cytotoxicity,
and easy surface functionalization. These properties prove their potential as a valid alternative to the
current CA systems used at the clinical stage, mostly in those cases where the poor pharmacokinetics
profile and potential toxicity of Gd3+ soluble forms can become an issue (e.g., patients with renal
failure). In this context, future studies will be focused on long-term in vivo stability and potential
toxicity of this novel paramagnetic nanocomposite.
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